Pluristem Continues to Strengthen Its Position in Japan – Granted Two Key Cell Therapy Patents
Pluristem Therapeutics Inc. announced that the Japan Patent Office has granted the company two key patents addressing Pluristem’s core technology of three-dimensional expansion methods for producing therapeutic cell products derived from placental or fat cells and the use of placenta-derived cells grown with this 3D technology to treat disorders of the hematopoietic system, such as disorders caused by exposure to radiation or chemotherapy, and failed engraftment of hematopoietic stem cell transplants.
TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TG-1101 in the United States
TG Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued a patent for the composition of matter of TG-1101, the company’s novel, glycoengineered monoclonal antibody. The patent, U.S. Patent No. 9,234,045 specifically covers the composition of TG-1101, and its use for treating various forms of CD20 expressing leukemia and lymphoma, including chronic lymphocytic leukemia and various types of non-Hodgkin’s lymphoma, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma.
Antibody Therapy Reduces Cancer Stem Cells in Multiple Myeloma
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.
New Biomarker Data to Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-Dose IL-2 Immunotherapy, including Those over 60 Years of Age
Scientists from Gothenburg University, Sweden will report data on an immune mechanism-based biomarker to predict the potential efficacy of treatment with Ceplene® in the difficult-to-treat above 60 year old population with AML.